Q32 Bio Raises $10.5M, Holds $50.8M Cash and Doses First Open-Label Extension Patient
QTTB•Q32 Bio is on-track to report 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial by mid-2026 and has dosed the first patient in the open-label extension. It raised $10.5 million via a registered direct offering and held $50.8 million in cash at March 31, 2026, funding into 1H 2028.
1. Financial Highlights
Q32 Bio closed a $10.5 million registered direct offering and raised an additional $14.2 million through its ATM program after quarter-end. With $50.8 million cash at March 31, 2026, and guaranteed near-term milestone payments from the ADX-097 asset sale, the company expects funding into 1H 2028.
2. SIGNAL-AA Phase 2a Part B Progress
Part B of the SIGNAL-AA trial evaluating bempikibart in 33 patients with severe alopecia areata remains on-track for a 36-week topline readout by mid-2026. Preliminary pharmacokinetic data show steady state drug levels nine weeks earlier versus Part A, and the first patient has entered the open-label extension.
3. Clinical Development Pathway
Efficacy will be assessed by mean SALT score change at week 36 with follow-up to week 52 ahead of OLE enrollment. Positive topline outcomes could enable advancement into pivotal trials pending mid-year data review.
